Table 2.
Anti-TSP IgG > 33.8 BAU/mL at different time-points
| HCs (40) | pwMS on OCR (28) | pwMS on FNG (19) | p | |
|---|---|---|---|---|
| T1 (8 weeks after first vaccine dose) number (%) | 40 (100) | 18 (64.3) | 10 (52.6) |
< 0.001* < 0.001** 0.5*** |
| T2 (16 weeks after first vaccine dose) number (%) | 40 (100) | 16 (57.1) | 10 (52.6) |
< 0.001* < 0.001** 0.7*** |
| T3 (24 weeks after first vaccine dose) number (%) | 40 (100) | 12 (42.9) | 6 (31.6) |
< 0.001* < 0.001** 0.5*** |
| T0b (within 8 weeks before booster dose) | 40 (100) | 12 (42.9) | 6 (31.6) |
< 0.001* < 0.001** 0.5*** |
| T1b (within 8 weeks after booster dose) | 40 (100) | 16 (57.1) | 16 (84.2) |
< 0.001* 0.03** 0.06*** |
Comparisons were performed by means of the fisher exact test. Significant values are reported in bold
HCs healthy controls; pwMS people with multiple sclerosis; OCR ocrelizumab: FNG fingolimod; Anti-TSP IgG anti-trimeric spike protein specific immunoglobulin G; BAU/mL binding arbitrary unit per mL
*Comparison between HCs and pwMS on OCR
*Comparison between HCs and pwMS on FNG
*** Comparison between pwMS on OCR and pwMS on FNG